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The limited loading of capillary electrophoresis (CE) leads to relatively poor concentration 
limits of detection. In this work a unique method for analyte preconcentration with capillary 
electrophoresis-mass spectrometry (CE-MS) is described. A cartridge containing an impreg- 
nated membrane is installed at the inlet of the CE capillary, and we term this approach 
membrane preconcentration capillary electrophoresis-mass spectrometry (mPC-CE-MS). The 
analysis of in vivo derived metabolites, peptides, and proteins is described showing the wide 
applicability of the technology in the analysis of numerous compound classes ranging in 
molecular weight from 200-60,000 u. In particular, we describe the direct rnPC-CE-MS 
analysis of urine obtained from a patient receiving the neuroleptic drug haloperidol. Three 
metabolites were found in the urine, and two of them are implicated in the Parkinsonian-like 
side effects caused by taking this drug. The technique is also applied to the analysis of major 
histocompatibility complex class I peptides obtained from EG-7 cells. Furthermore, the 
clinical potential of this approach is described by the direct analysis of urine from a patient 
suffering from multiple myeloma, as well as aqueous humor derived from a patient 
undergoing surgery. Finally we show that the use of mPC-ME-MS in conjunction with either 
analyte stacking (small organic molecules such as metabolites) or moving-boundary transient 
isotachophoresis (peptides and proteins) afler analytes have been eluted from the adsorptive 
membrane affords optimal performance and no compromise in CE mass spectrometry 
performance. 
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apillary electrophoresis (CE) separations are 
performed in narrow bone capillaries (- 5-100- 
pm i.d.1. A high voltage (5-30 kV) is applied 
across the capillary and anlytes are separated based (to 
a first approximation) on their different charge-to-mass 
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ratios [l, 21. CE is characterized by low solvent con- 
sumption (nanoliters to microliters per run) and mini- 
mal sample loss due to the small volume (l-2 PL) and 
surface area of the capillary. However, the small, finite 
volume of the CE capillary also leads to poor concen- 
tration limits of detection (CLOD). This fact has proved 
to be a major limitation of CE in the analysis of many 
analyte mixtures [3] and is brought about because 
resolution and separation efficiency are readily com- 
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promised when sample injection of greater than 
- 1.5-2% of the CE capillary volume is attempted [4, 
51. Hence, analysis of sample volumes of only * l-100 
nL are common in CE. This dramatically contrasts with 
the - l-100-PL injections carried out in capillary 
high-performance liquid chromatography (HPLC). 
Therefore, while it is recognized that both CE and 
HPLC offer orthogonal modes to separate analyte mix- 
tures, the latter is often the method of choice for many 
mixtures that contain low concentrations of analytes. 
The same limited CLOD also applied to the on-line 
capillary electrophoresis-mass spectrometry (CE-MS) 
of analyte mixtures. The development of CE-MS was 
pioneered independently by Smith et al. [6, 71, who 
used a coaxial sheath liquid approach, and by Henion 
and co-workers [8, 91, who developed the liquid junc- 
tion interface. Since the first report of on-line CE-MS, it 
has undergone considerable development in both in- 
strumentation and applications and was the subject of 
a recent review [lo]. However, only transient isota- 
chophoresis (tITP) introduction of sample onto the CE 
capillary has been explored in terms of attempting to 
improve CLOD in CE-MS [ll-151. This injection tech- 
nique is ultimately implemented as the voltage is 
applied across the CE capillary, which subsequently 
results in focusing of the injected analyte zone. This is 
brought about due to the faster mobilities of ions in 
the leading and trailing buffer zones sandwiching the 
analyte zone. However, even under optimal conditions 
this approach only allows sample volumes of = 1 PL 
to be introduced onto the CE capillary. 
To overcome the limited loading capacity of con- 
ventional CE, on-line analyte concentration was devel- 
oped. It was pioneered by Guzman et al. [16] and 
subsequently developed by us and others; the subject 
was recently reviewed [3]. Most groups have utilized a 
small bed (l-2 mm) of solid phase packing at the inlet 
of the CE. However, it has been demonstrated that 
compromised CE performance occurs when solid phase 
packing is used [17-231 since it necessitates, from a 
practical perspective, the use of a relatively large bed 
volume. This has also, in part, been attributed to an 
increased back pressure that reduces hydrodynamic 
flow within the CE capillary. In addition, the flow of 
ions may be impaired by the solid phase resulting in 
reduced or anomalous electro-osmotic flow (EOF). We 
have also previously reported that large volumes of 
organic solvent required to remove analytes from the 
solid phase within the CE capillary can also lead to 
reduced EOF [24, 251. These factors can result in the 
broadening of analyte zones, compromised resolution, 
and loss of separation efficiency. 
To reduce and ensure a consistent bed volume of 
adsorptive phase, we have developed and demon- 
strated the use of a preconcentration cartridge that 
contains a membrane impregnated with a suitable sta- 
tionary phase, as shown in Figure 1. The cartridge fits 
at the inlet of the conventional CE capillary, and we 
have termed this approach membrane preconcentra- 
tion-capillary electrophoresis (n-PC-CE) [3, 17-20, 261. 
We have also demonstrated the applicability of this 
technique on-line with mass spectrometry (rnPC-CE- 
MS). By using this approach, sample contaminants 
(e.g., biological matrix components or chemical 
reagents) can be pre-eluted from the phase and washed 
through the CE capillary prior to analyte elution and 
analysis. Such on-line sample cleanup reduces sample 
handling and improves analyte recovery. 
In the present study, we demonstrate the broad 
applicability of ml?C-CE and on-line with mass spec- 
trometry (mPC-CE-MS) in the analysis of biologically 
derived drug metabolites, peptides, and proteins. Fur- 
thermore, we describe mPC-CE-MS in conjunction with 
either analyte stacking or moving-boundary tITP after 
analytes have been eluted from the adsorptive mem- 
brane. 
Experimental 
Materials 
Haloperidol [HAL, 4-(4-chlorophenyl)-1-[4-(4-fluoro- 
phenyl-4-oxobutyll-4-piperidinoll, zinc sulfate, ammo- 
nium hydroxide, and potassium hydroxide were ob- 
tained from the Sigma Chemical Co. (St. Louis, MO). 
Gold grade ammonium acetate and glacial acetic acid 
(99.9% grade) were obtained from Aldrich Chemical 
Co. (Milwaukee, WI). HPLC grade solvents methanol, 
acetonitrile, and water were obtained from Baxter 
(Minneapolis, MN). High purity water was purchased 
from Burdick and Jackson (Muskegon, MI). 4-(4-&lore 
phenyl)-l-[4-(4-fluorophenyl)-4-oxobutyl]-pyridinium 
(HP+) and 4-(4-chlorophenyl)-1-[4-(4-fluorophenyl4 
hydroxybutyll4-piperidinol (RHAL) were a gift from 
Professor J. Gorrod (University of London). 4-(4- 
chlorophenyl)-l-[4~4-fluorophenyl)4-hydroxybutyl]-l- 
pyridinium (RI-II’+) was a gift from Professor N. 
Castagnoli, Jr. (VPIST). The 3M EmporeTM polymeric 
styrene divinyl benzene copolymer (SDB), C-18, and 
C-8 membranes were obtained from Varian (Harbor 
City, CA). Polyimide-coated fused silica capillary tub- 
ing was purchased from Polymicro Technologies 
(Phoenix, AZ). Teflon tubing was obtained from 
Chromtech (Apple Valley, MN). 
In Vivo Derived Samples 
Haloperidol. Urine was obtained from a 27-year-old 
female patient who was receiving 0.5 mg/day of the 
neuroleptic drug haloperidol. The urine was kept 
frozen at - 20 “C until ready for analysis. Urine aliquots 
(lo-20 pL) were injected directly onto the mPC-CE 
cartridge by using pressure (20 lb/in.‘) injection. 
Major histocompatibility complex (MHC) class I peptides. 
10s EG-7 cultures cells were “milked” and peptides 
were treated and collected as described previously 
1271. They were subsequently subjected to HPLC frac- 
tionation prior to mI?C-CE-MS analysis. 
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Figure 1. Schematic of mF’C-CE-MS by using a Finnigan-MAT ES1 interface source. The mPC-CE 
cartridge is shown magnified for clarity (not to scale). 
Bence-Jones protein. Urine was collected from a male 
patient suffering from multiple myeloma. Urine was 
stored at - 20 “C until ready for analysis. Urine aliquots 
(l-5 PL) were injected directly onto an mPC-CE car- 
tridge by using a polybrene-coated CE capillary to 
effect separation. 
Aqueous humor proteins. Aqueous humor was ob- 
tamed from the anterior chamber of the eye by using 
30 gauge cannula inserted through a previously made 
paracentesis. Approximately 0.15 mL of aqueous hu- 
mor/eye was obtained, and this was stored in an 
Eppendorf tube at -70 “C until ready for analysis. 
Approximately 10 PL of aqueous humor was analyzed 
directly, without any further sample manipulation, by 
using mPC-CE-MS employing a polybrene-coated CE 
capillary. 
Membrane Preconcentration-Capillary 
Electrophoresis-Mass Spectromet y 
The preconcentration cartridge used in these experi- 
ments was prepared from uncoated fused silica tubing 
pretreated with potassium methoxide, methanol, and, 
finally, CE separation buffer. A piece of polymeric 
styrene divinyl benzene (SDB) membrane was cut by 
using a 22 gauge blunt-tipped hypodermic needle. The 
membrane remained in the needle until insertion into 
the midpoint of a short length (- 1 cm) of Teflon 
tubing (300-pm i.d. x 1500-pm 0.d.). To install the 
membrane, the needle is placed over either end of the 
Teflon tube, and, with a small length of fused silica 
(positioned inside the hypodermic needle), it is care- 
fully pushed into position. Provided this procedure is 
followed with adequate attention, the piece of mem- 
brane will hold its shape and completely fill the cross 
sectional area of Teflon tube. Final cartridge assembly 
is achieved by inserting the fused silica capillary (50 
pm i.d. x 365 pm i.d. x 1.5 cm long) into each of the 
Teflon tube. During this process, care is taken to nei- 
ther compress the membrane nor scrape the walls of 
the Teflon tubing since both could result in blockage of 
the cartridge and low hydrodynamic flow. Also for 
this final step of cartridge construction, provided the 
inside diameter of the Teflon and outside diameter of 
the fused silica are similar, the cartridge will be leak- 
free with a push-fit connection. This latter approach 
negates he need for gluing the fused silica in position. 
The push-fit cartridge is advantageous since, if the 
piece of membrane becomes heavily contaminated, it 
is easily replaced. Prior to installation the membrane 
was activated by washing with MeOH, then CE sepa- 
ration buffer. The entire mPC-CE capillary was then 
conditioned under high pressure (20 lb/in.‘> for 10 
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min with CE separation buffer. All subsequent capil- 
lary treatments and sample loading, washing, and elu- 
tion were also carried out under high pressure (20 
lb/in2). 
The method of analysis included a cleaning regime 
of methanol (0.2 min) and separation buffer (5 min) 
followed by a high pressure injection of the mixture to 
be analyzed. The capillary was then washed with sepa- 
ration buffer for 5 min and analytes were eluted from 
the packing material with either 80 : 20 MeOH : H,O or 
100% methanol followed by a plug of CE separation 
buffer. CE separations were performed by using a 
Beckman (Fullerton, CA) P/ACE 2100 coupled via a 
Beckman CE-MS power supply and interfaced to a 
Finnigan-MAT (Bremen, Germany) electrospray source. 
All analyses were carried out on either a MAT 95Q 
or MAT 900 (Bremen, Germany) mass spectrometer. 
The MAT 95Q is of BEQ,Q2 configuration (where B is 
the magnet, E is the electrostatic analyzer, Q, is an 
rf-only octapole collision cell, and Qz is quadrupole 
mass filter). The MAT 900 is of EB configuration 
equipped with a position of time-resolved ion counter 
(PATRIC) scanning array detector. A Finnigan-MAT 
electrospray ionization (ES11 source was used, and this 
device employs a spray needle that is floated and 
consists of an ES1 voltage of 3.4 kV referenced to an 
accelerating voltage of 4.8 kV. A heated metal capillary 
(- 255 “0 completes the first stage of separa- 
tion of the atmospheric (API) spray region. A skimmer 
is positioned beyond this capillary as a second stage of 
separation between the API region and the mass spec- 
trometer vacuum. Ions that transfer into the mass 
spectrometer ion source initially enter as octapole that 
aids focusing. 
The source was used in a positive ion mode 
throughout, and the sample needle of the ES1 source 
was replaced by the CE capillary from which 2-3 mm 
of the polyimide coating had been removed from the 
mass spectrometer end with hydrofluoric acid. A sheath 
liquid of isopropanol : water : acetic acid (60 : 40 : 1 
v/v/v) at a flow rate of 2-3 pL/min was used to 
boost the flow through the ES1 needle and serve as the 
counterelectrode of the CE capillary. All other condi- 
tions are described in the appropriate figure legends. 
Raw electrospray ionization-mass spectrometry (ESI- 
MS) data was deconvoluted by using standard 
Finnigan-MAT software. 
Results and Discussion 
In attempting to design and construct a new precon- 
centration-capillary electrophoresis (PC-CE) approach, 
factors that would decrease or remove all of the poten- 
tial problems associated with the solid phase PC-CE 
capillary were considered. Hence, we have found that 
by minimizing the volume of the adsorptive phase and 
by using an appropriate coated/impregnated mem- 
brane, it is possible to reduce the volume of elution 
solvent required for efficient removal of analytes from 
the phase. Therefore, adverse effects due to the pres- 
ence of large volumes of organic solvent on CE perfor- 
mance can be significantly reduced. For convenience, 
the membrane is installed in a Teflon cartridge system, 
as shown in Figure 1. This facilitates the ready removal 
of the cartridge to allow CE capillary cleaning/condi- 
tioning and activation of the adsorptive membrane. It 
is possible to load and concentrate analytes on the 
mPC-CE cartridge by using solution volumes in excess 
of 100 PL [28]. Furthermore, once analytes are concen- 
trated on the membrane adsorptive phase, it is possi- 
ble to effect on-line sample cleanup prior to CE analy- 
sis. This is particularly important for many in vivo 
derived biological samples from body fluids such as 
urine, plasma, bile, and cerebrospinal fluid (CSF). In 
part, this is due to the presence of high salt concentra- 
tions in such fluids, which can dramatically effect CE 
analyte separations by degrading the efficiency of the 
stacking and focusing processes that occur in the CE 
capillary. 
The mPC-CE cartridge is also compatible with on- 
line CE-MS (mPC-CE-MS) [19, 20, 261. In our case we 
use the coaxial flow electrospray interface (ESI) con- 
figuration previously described by Smith et al. [6, 71, 
and this is also shown schematically in Figure 1. Opti- 
mal configuration conditions for this CE-ESI-MS inter- 
face, as well as means to enhance sensitivity limits 
have been reported elsewhere [29, 301. 
Membrane Preconcentration-Capillary 
Electrophoresis-Mass Spectrometry 
We have previously described the use of CE [ 13,31-331 
and CE-MS [29, 34-361 in the analysis of in vitro 
derived drug and xenobiotic metabolite mixtures. 
However, the analysis of in vivo produced metabolites 
by CE-MS often results in only limited information 
being obtained on the metabolic transformations of the 
parent drug. This is predominantly due to the dilute 
concentration of metabolites, as well as the limited 
loading capacity of the CE capillary. This was high- 
lighted by the CE-MS analysis of a urine sample ob- 
tained from a female patient taking 0.5 mg/day of the 
neuroleptic drug haloperidol (HAL) 1351. An aliquot (3 
mL) of the urine was subjected to off-line solid phase 
extraction and part of the sample was analyzed by 
CE-MS by using tITP as the method of injection. Even 
by using a position and time-resolved ion counter 
(PATRIC) array detector in static mode to ensure maxi- 
mum sensitivity, it was only possible to detect unme- 
tabolized parent drug, as well as a known metabolite, 
reduced haloperidol (RHAL). This approach had sev- 
eral limitations including: 
1. Sample losses due to off-line concentration ap- 
peared to be considerable. 
2. Static PATRIC detection did not allow detection of 
metabolites outside the 8% mass range. 
J Am Sac Mass Spectrom 1997, 8, 1524 ENHANCED SAMPLE LOADING BY mPC-CE/MS 19 
/ 
SDS Membrane 
P&ethylene 
Tubing 
3. The limited loading capacity of conventional CE 
capillaries, even by using stacking or focusing injec- 
tion techniques (e.g., tITP), was insufficient for the 
analysis of low concentrations of analytes derived 
from human body fluids such as urine. 
To overcome these problems, we attempted the 
mPC-CE-MS analysis of the same urine sample. Typi- 
cally, analytes are loaded onto the mPC-CE cartridge 
on-line with the mass spectrometer in an aqueous 
buffer/solvent and subsequently adsorb onto the im- 
pregnated membrane. Hence, 10 PL of urine was di- 
rectly injected (20 lb/in2) onto the mPC-CE-MS setup. 
After the sample was loaded, the membrane was 
washed with aqueous CE separation buffer (50-mM 
NH,OAc, 10% MeOH: 1% AcOH) for 5 min to remove 
any salts, urea, and other hydrophilic matrix compo- 
nents from the membrane allowing on-line sample 
cleanup. Finally the analytes were removed from the 
membrane with 80 nL of MeOH and subjected to 
CE-MS by using the PATRIC array detector in scan- 
ning mode. 
It should be noted that previous attempts at loading 
high volumes of analyte solutions by using mPC-CE 
resulted in some compromised CE performance high- 
lighted by slight peak broadening. However, by em- 
ploying mPC-CE in conjunction with analyte stacking 
after analytes were eluted from the membrane [311, no 
compromise in performance occurred. When small or- 
ganic molecules, such as drug metabolites, are eluted 
from the membrane in organic solvent (e.g., MeOH), 
analyte stacking occurs when the CE voltage is ap- 
plied. This is due to the fact that analytes are now in a 
low conductivity solution relative to the separation 
buffer, which leads to a high field strength across the 
organic zone. This results in a rapid migration of 
analytes through the organic solvent, which ultimately 
leads to localized stacking, and this is shown schemati- 
cally in Figure 2. 
The mPC-CE-MS analysis of the urine sample, em- 
ploying full scan (125-450 ul mass detection, revealed 
ions at m/z 376.4, 380.3, 354.3, and 356.3, all of which 
exhibited a “Cl isotope contribution. These responses 
could tentatively be assigned as protonated molecular 
weight ions corresponding to unmetabolized parent 
drug HAL, the known metabolite RHAL, and two 
Figure 2. Schematic of analyte stacking 
for use in conjunction with mPC-CE-MS 
after analytes have been eluted from the 
adsorptive membrane in a high organic 
solvent zone. 
pyridinium species HP’ and RHP+, respectively (see 
Figure 3). The structural characterization of these 
metabolites was carried out by using membrane pre- 
concentration-capillary electrophoresis-tandem mass 
spectrometry (mPC-CE-MS/MS) in the linked scan 
mode, and these data will be reported in detail else- 
where. These results are consistent with the recently 
published work of Pond and co-workers [37] and 
s , m/z=3563 
75.5 { 
m/z= 3543 
I HP’ 
0 I 
5 IO 15 20 25 30 
Time (min) 
Figure 3. mPC-CE-MS analysis of 10 PL of urine obtained from 
a patient taking 0.5 mg’day of the neuroleptic drug haloperidol 
(HAL). The mPC-CE capillary was uncoated fused silica (50 pm 
i.d. x 80 cm length) with a C-18 impregnated membrane installed 
in the mI’C-CE cartridge at the CE inlet. Sample cleanup was 
effected by washing with 10 FL of separation buffer. Analyte 
elution was with 100% methanol (80 nL) followed by separation 
buffer (50.mM NH,OAc: 10% methanol: 1% AcOH). Separation 
voltage was 210 V/cm. A sheath liquid containing 
isopropanol : H 2O : AcOH (60 : 40 : 1 v/v/v) was delivered at 2 
pL/min. ES1 voltage was 3.4 kV, and referenced to the accelerat- 
ing voltage of 4.8 kV, making a total voltage of 8.2 kV. The 
mstrument resolution was - 1000 and the scan range was 
1255450 u at 2 s per decade. Detection by scanning PATRIC 
detector used an 8% window. Note that the signal for RHAL is 
the ‘7C1 isotope contribution (m/z 380) of MH’ = 378. 
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Castagnoli and co-workers [38], who reported finding 
HP+ and RHP+ present in both humans and animals. 
The detection of the two pyridinium metabolites is 
indicative that HAL undergoes metabolic conversion 
via an active intermediate that is similar in nature to 
MPTP metabolism. A metabolite of l-methyl-4-phenyl- 
1,2,3,6-tetrahydropyridine (MPTP) is a known and 
powerful inducer of Parkinsonian-like symptoms in 
both animals and humans. 
Analysis of Membrane Preconcentrution-Capilla y 
Electrophoresis-Mass Spectrometry Major 
Histocompatibility Complex Class 1 Peptides 
The use of n-PC-CE-MS in the analysis of dilute syn- 
thetic peptide mixtures has recently been demon- 
strated [19, 201. However, to efficiently remove 
peptides from the adsorptive membrane, an elution 
solvent that contains some water (e.g., 80: 20 v/v 
methanol : H,O) is necessary. Furthermore, optimal 
peptide recovery is achieved only when > 50 nL of 
such a solvent mixture is used 1201. This relatively 
large volume of elution solvent, along with the ineffi- 
cient analyte stacking that occurs, results in some peak 
broadening and loss of analyte resolution. Therefore, 
the use of moving-boundary tITP, in conjunction with 
mPC-CE-MS, was attempted after the peptides were 
eluted from the adsorptive membrane. In this case, 
moving-boundary tITP conditions are used to stack 
analyte zones and also aid the dispersion of the or- 
ganic elution solvent. It is effected by elution of the 
peptides from the membrane between zones of a lead- 
ing stacking buffer (LSB), typically O.l-5% NH,OH in 
water, and a trailing stacking buffer (TSB), typically 
1% acetic acid in water or CE separation buffer (as 
shown schematically in Figure 4). We have also 
demonstrated that variation of the ratio of concentra- 
tion and volume of LSB, elution solvent, and TSB can 
be used to manipulate the analyte migration time, 
peak width, and resolution [3]. 
The use of mPC-CE-MS in conjunction with mov- 
ing-boundary tITP was utilized in the analysis of ma- 
jor histocompatibility complex (MHC) class I peptides. 
These peptides are important signals of the immune 
system [39l. However, characterization of individual 
peptides, as well as sequence determination, presents a 
formidable challenge. It has been reported that MHC 
class I glycoproteins can bind in excess of lO,OOO-15,000 
peptides, each of unique sequence. Furthermore, many 
of these peptides are only extracted in low concentra- 
tions (lo-i5-10- l8 M) [40]. 
The strategy we have developed for characterizing 
and ultimately sequencing MHC class I peptides is 
summarized in Figure 5. Specifically, HPLC fractions 
were collected and subjected to removal of the acetoni- 
trile under vacuum. Resultant peptide solutions 
(- 40-70 CCL) are diluted with CE separation buffer 
(2-mM NH,OAc: 1% acetic acid, pH 2.9) to a final 
volume of * 150 pL. An aliquot of this solution (50 
PL) is subjected to mPC-CE-MS for determination of 
the peptide molecular mass. Off-line sample loading 
and cleanup (with CE separation buffer) were used, 
since the flow rate in the 25-pm-i.d. mPC-CE capillary 
was only 120-150 nL/min. On-line loading of 50 PL of 
sample in this capillary would take up to 5.5 h. How- 
ever, the flow rate achieved in an rnPC cartridge loaded 
off-line can be much higher, since these devices can 
withstand relatively high pressures ( N 60 lb/in.*>. 
Furthermore, system back pressure is also reduced, 
and up to 100 /*L of sample can often be loaded 
off-line in < 5 min, thus significantly reducing analy- 
sis time. Since the flow in an mPC cartridge is bidirec- 
tional, sample loaded with a reverse flow followed by 
cleanup in the forward direction ensures that sample- 
derived particulate matter is flushed from the mPC 
cartridge prior to assembly of the mPC-CE capillary. 
This improves the reproducibility of mPC-CE-MS by 
reducing the tendency of the cartridge to clog. 
The rnPC-CE-MS analysis of an extract from 10s 
EG-7 cells was carried out. Specifically, the cells were 
Polyethylene 
Tubing Elution Solvent + Peptide 
mPC-CE Cartridge 
Figure 4. Schematic of tITP conditions for use with mPC-CE-MS analysis of peptides after the 
peptides have been eluted from the adsorptive membrane. 
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Figure 5. Typical strategy for isolating and characterizing MHC 
class I peptides by mPC-CE-MS. 
repeatedly “milked“ by using the method described 
by Storkus et al. [271. The peptides obtained by this 
process were combined and subjected to fractionation 
by reversed phase HPLC as described above. Subse- 
quently, lOO-PL aliquots of the HPLC analysis were 
collected. Approximately 40 PL of one fraction, which 
was a minor shoulder of a major UV absorbing peak, 
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we removed and the CH,CN solvent was evaporated 
under partial vacuum to afford N 10 PL of aqueous 
solution. The fraction was then diluted to 40 ,uL of 
separation buffer (2-mM NH,OAc: 1% AcOH), and 
50% of this sample was pressure injected onto the 
mPC-CE cartridge. Subsequently, the MHC class I pep- 
tides were eluted from the styrene divinyl benzene 
(SDB) membrane with - 80 nL of 80 : 20 MeOH : H,O 
sandwiched between an LSB of 0.1% NH,OH and a 
TSB of 1% AcOH. This elution profile ensures efficient 
stacking/focusing of the peptides in the analyte zone 
on application of the CE voltage. The mPC-CE-MS 
analysis revealed a myriad of peptide responses, as 
seen in Figure 6. This analysis reveals the complexity 
of MHC class I peptide analysis and strongly indicates 
that such analyses should only be carried out in con- 
junction with a targeted bioassay approach. 
Membrane Preconcentrution-Capillary 
Elecfrophoresis-Muss Specfromefry of Clinically 
Derived Proteins 
The use of mPC-CE-MS for basic research studies (e.g., 
structural characterization of MHC class I peptides) is 
an important application of this technology. However, 
800 
2o:so 21:40 22:30 23~20 24:10 25~00 
Time (mins) 
Figure 6. mPC-CE-MS analysis of 25 PL of a HPLC fraction from 10’ EG-7 cells of MHC class I 
peptides. The mPC-CE capillary was uncoated fused silica (25-pm id. X 67-cm length) with a SDB 
membrane. Analyte elution was by use of - BO-nL 80 : 20 MeOH : H,O, sandwiched between a LSB 
of 0.1% NH,OH and a TSB of 1% AcOH followed by separation buffer (2-mM NH,OAc: 1% AcOH). 
All other conditions were the same as for Figure 3 except separation voltage was 250 V/cm, scan 
range was 304I-1300 u at resolution of - 300, by using the electron multiplier as the detector. 
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the direct analysis of physiological fluids (e.g., urine, 
plasma, bile, etc.) by these techniques shows great 
potential for determining diagnostic disease biomark- 
ers. One particular application of mIT-CE-MS in this 
regard is the direct analysis of patient urine for diag- 
nosis of multiple myeloma. This disease state is a 
disseminating malignancy of plasma cells that is sus- 
pected to be caused by exposure to radiation and/or 
repeated stimulation of reticuloendothelial cells [41]. 
Diagnosis is by the presence of multiple tumor foci on 
bone marrow biopsies and the secretion of monoclonal 
immunoglobulin light chains (Bence-Jones protein) in 
patient urine. Quantification of these proteins in urine 
yields evidence of disease progression and is an excel- 
lent indicator of the effects of chemotherapy. Further- 
more, the concentration of monoclonal immunoglobu- 
lin light chains proteins in patient urine reflects the 
degree of plasma cell burden and may be used to flow 
amyloidosis and nephrotic syndrome. 
Current methodologies for analysis of these proteins 
involve the collection of a 24-h urine specimen. After 
suitable concentration, this sample is subjected to anal- 
ysis of electrophoresis, immunoelectrophoresis, or 
immunofixation. More frequently, the presence of 
monoclonal immunoglobulin light chain proteins is 
confirmed by using at least two of these techniques 
[41]. Direct analysis of patient urine as a confirmatory 
test would have sizable benefits in terms of reduced 
time of analysis as compared to existing assays. Urine 
from a patient previously diagnosed with multiple 
myeloma was analyzed directly by mlT-CE-MS with- 
out any off-line pretreatment. Approximately 1.5 PL of 
urine was injected onto the mlT-CE cartridge and 
thoroughly washed with w 50-PL H,O followed by 
separation buffer. Subsequently the analytes were 
eluted from the membrane with 80 : 20 MeOH : H,O 
and subjected to CE-MS, and the deconvoluted mass 
spectrum is shown in Figure 7. The deconvoluted 
spectrum showed a series of monoclonal immunoglob- 
ulin light chain proteins. Furthermore, the mass dif- 
ference between ions at m/z 23,941 and 24,144 is 
* 203 and indicates the heterogeneity of a glycopro 
tein (a mass difference of - 203 representing the pos- 
sible presence of a glucosamine residue). This example 
not only demonstrates the applicability of mIT-CE-MS 
for clinical assay, but shows the high level of informa- 
tion that can be achieved by this technology. 
The potential application of mlT-CE-MS in the clin- 
ical diagnosis of disease states is substantial. In part, 
this is due to the fact that the technique can be utilized 
in the direct analysis of any physiologically derived 
body fluid. This is further demonstrated by the direct 
mIT-CE-MS analysis of aqueous humor obtained from 
a patient undergoing eye surgery. The chemical com- 
position of human aqueous humor is still poorly un- 
derstood, mainly due to the limited sample amounts 
that can be collected. However, it has been suggested 
that the chemical content of this fluid may play a role 
in drainage of the human eye. In particular, the protein 
5 6C- m/z=23941 
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Figure 7. mPC-CE-MS analysis of 1.5 FL of urine from a patient 
suffering fro multiple myeloma. The deconvoluted spectrum 
shows the presence of Bence-Jones protein. The mPC-CE capil- 
lary was polybrene-coated silica (50-pm i.d. x 80-cm length) with 
a SDB impregnated membrane installed at the CE inlet. Sample 
cleanup was effected by washing with CE separation buffer (1% 
formic acid) followed by analyte elution with - 80-nL methanol: 
H,O : AcOH (80 : 20 : 1 v/v/v) and 100-nL formic acid. Separa- 
tion voltage was 272 V/cm, with simultaneous application of 
low pressure (0.5 lb/in.*). All other conditions were the same as 
in Figure 3 except the scan range was 700-2000 u. 
content of aqueous humor may contain important fac- 
tors in this process [42]. Hence, any method that can 
readily determine the protein content of aqueous hu- 
mor would be great benefit. 
In this specific case, we took 7 PL of human aque- 
ous humor and pressure injected it directly, without 
any pretreatment, onto a C-8 silica-based impregnated 
membrane. The membrane containing the aqueous hu- 
mor analytes was subsequently washed for 10 mm 
with separation buffer (1% acetic acid). Analytes were 
eluted from the membrane with 80: 20 MeOH: H,O 
and subjected to CE separation in a polybrene-coated 
capillary with final detection by ESI-MS. The mlT-CE- 
MS ion electropherogram is shown in Figure 8. A 
number of ion responses were observed including 
singly charged species at m/z 758, 760, and 782. Fur- 
thermore, two components were tentatively identified 
as human serum albumin (MHE’ = 1338) and P-2 
microglubulin (MH, 1 1 + = 1067). Deconvolution of the 
ion series containing m/z 1067 revealed a molecular 
weight of 11,729 u corresponding to the oxidized form 
of +nicroglubulin that contains a single cysteine 
bridge (see Figure 9). Characterization of the other 
components present in the mixture is currently in 
progress. 
Conclusions 
A major perceived limitation of CE was the limited 
loading capacity of conventional CE capillaries which 
resulted in poor CLOD. However, the development of 
mIT-CE-MS now routinely allows sample volumes of 
l-150 PL to be introduced onto the CE capillary. 
Employing a membrane base impregnated with a suit- 
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Figure 8. mPC-CE-MS direct analysis of 7 FL of human aque- 
ous humor. The mPC-CE capillary was polybrene-coated silica 
@l-pm i.d.X 70-cm length) with a C-8 silica-based membrane. 
Analyte elution was by addition of 60 : 20 MeOH : H 20, followed 
by separation buffer (1% AcOH). All other conditions were the 
same as for Figure 3 except separation voltage was 240 V/cm 
and scan range was 700-2500 u at a resolution of - 1500. 
able adsorptive phase allows concentration of analytes, 
as well as on-line sample cleanup. Furthermore, select- 
ing the appropriate adsorptive phase allows precon- 
centration of selected classes of compounds. For 
instance, for small organic molecules, an SDB impreg- 
nated membrane was used, whereas a C-8 silica-based 
membrane was used in the analysis of proteins. 
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Figure 9. Deconvoluted mPC-CE-MS spectrum of a multiple 
charge ion series at m/z 978.5, 1067.3, 1173.9, and 1304.1. The 
deconvoluted spectrum reveals the molecular weight of the pro- 
tein to be the oxidized form of p2 microglobulin. 
The versatility of mPC-CE-MS in the analysis of in 
vivo derived compounds is highlighted by the results 
obtained from haloperidol metabolites in urine, MHC 
class I peptides from EG-7 cells, and proteins derived 
from urine and human aqueous humor. The potential 
of mPC-CE-MS in the direct analysis of complex mix- 
tures is demonstrated and the potential of this ap- 
proach to determine new biological markets of disease 
states is indicated. 
Acknowledgments 
We thank Diana Ayerhart (Mayo Clinic) for her help in preparing 
this manuscript. We gratefully acknowledge funding from Mayo 
Foundation, Beckman Instruments, and Finnigan-MAT. 
References 
1. Guzmazn, N. A., Ed. Capillary Electrophoresis Technology; 
Dekker: New York, 1993. 
2. Weinberg, R. Practical Capillary Electrophoresis; Academic: San 
Diego, 1993. 
3. Tomlinson, A. J.; Guzman, N. A.; Naylor, S. 1. Cap. Elec. 1995, 
2, 247. 
4. Cai, J.; El Rassi, Z. 1. Liquid Chromatogr. 1992, 15, 1179. 
5. Cai, J.; El Rassi, Z. J. Liquid Chromatogr. 1993, 16, 2007. 
6. Smith, R. D.; Olivares, J. A.; Nguyen, N. T.; Udseth, H. R. 
Anal. Chem. 1988, 60,434. 
7. Smith, R. D.; Loo, J. A.; Barinaga, C. J.; Edmonds, C. G.; 
Udseth, H. R. 1. Chmmutogr. 1989, 480, 211. 
8. Lee, E. D.; Mueck, W.; Henion, J. D.; Covey, T. R. 1. Chro- 
matogr. 1988, 458, 313. 
9. Johannson, I. M.; Huang, E. C.; Henion, J. D.; Zweigenbau, J. 
1. Chromatogr. 1991, 554, 311. 
10. Cai, J.; Henion, J. D. J. Chromatogr. A 1995, 703, 667. 
11. Smith, R. D.; Fields, S. M.; Loo, J. A.; Barinaga, C. J.; Udseth, 
H. R.; Edmonts, C. G. Electrophoresis 1990, II, 709. 
12. Tinke, A. P.; Reinhoud, N. J.; Niessen, W. M. A.; Tjaden, 
U. R.; Van der Greef, J. Rapid Commun. Mass. Spectrom. 1992, 
6,560. 
13. Benson, L. M.; Tomlinson, A. J.; Reid, J. M.; Walker, D. L.; 
Ames, M. M.; Naylor, S. 1. High Res. Chromatogr. 1993, 26, 
324. 
14. Lamoree, M. H.; Reinhoud, N. J.; Tjaden, U. R.; Niessen, 
W. M. A.; Van der Greef, J. Biol. Mass Spectrom. X994, 23,339. 
15. Locke, S. J.; Thibault, P. AnaL Chem. 1994, 66, 3436. 
16. Guzman, N. A.; Trebilcock, M. A.; Advis, J. P. J. Liquid 
Chromatogr. 1991, 14, 997. 
17. Tomlinson, A. J.; Benson, L. M.; Oda, R. P.; Braddock, W. D.; 
Riggs, B. L.; Katzmann, J. A.; Naylor, S. J. Cap. Elec. 1995, 2, 
97. 
18. Tomlinson, A. J.; Benson, L. M.; Braddock, W. D.; Oda, R. I’.; 
Naylor, S. 1. High Res. Chromatogr. 1995, 18, 381. 
19. Tomlinson, A. J.; Naylor, S. 1. Cup. Elec. 1995, 2, 225. 
20. Tomlinson, S. J.; Naylor, S. 1. Liquid Chromatogr. 1995, 18, 
3591. 
21. Tomlinson, A. J.; Benson, L. M.; Oda, R. P.; Braddock, W. D.; 
Strausbauch, M. A.; Wettstein, P. J.; Naylor, S. 1. High Res. 
Chromatogr. 1994 17, 669. 
22. Tomlinson, A. J.; Braddock, W. D.; Benson, L. M.; Oda, R. I’.; 
Naylor, S. 1. Chromatogr. B Biomed. Appl. 1995, 669, 67. 
23. Debets, A. J. J.; Mazereeuw, M.; Voogt, W. H.; van Iperen, 
24 TOMLINSON ET AL. J Am SW Mass Spectrom 1997,8,15-24 
D. J.; Lingeman, H.; Hupe, K.-P.; Brinkman, U. A. T. 1. 
Chromatogr. 1992, 608, 151. 
24. Tomlinson, A. J.; Benson, L. M.; Naylor, S. Liquid 
Chromatogr.-Gas Chromatogr. 1994, 12, 122. 
25. Tomlinson, A. J.; Benson, L. M.; Naylor, S. Am. Lab. 1994, 26, 
29. 
26. Tomlinson, A. J.; Naylor, S. I. High Res. Chromatogr. 1995, 18, 
384. 
27. Storkus, W. J.; Zeh, H. J.; Salter, R. D.; Lotze, M. T. J. 
Immunotherapy 1993, 14,94. 
28. Naylor, S.; Jameson, S.; Tomlinson, A. S. Proceedings of the 3rd 
International Symposium on Applied Mass Spectromety in the 
Health Sciences-European Tandem Mass Spectromety Confer- 
ence; Barcelona, Spain, July 1995. 
29. Tomlinson, A. J.; Benson, L. M.; Naylor, S. I. Cap. Elec. 1994, 
2, 127. 
30. Johnson, K. K.; Tomlinson, A. J.; Naylor, S. Rapid Commun. 
Mass. Spectrom. 1996, 20, 1159. 
31. Benson, L. M.; Tomlinson, A. J.; Naylor, S. J. High Res. 
Chromatogr. 1994, 27, 671. 
32. Tomlinson, A. J.; Benson, L. M.; Landers, J. P.; Scanaln, G. F.; 
Fang, J.; Gorrod, J. W.; Naylor, S. J. Chromntogr A 1993, 652, 
417. 
33. Naylor, S.; Benson, L. M.; Tomlinson, A. J. In Handbook of 
Capilla y Electrophoresis; Landers, J. I’., Ed.; CRC: Boca Raton, 
FL, 1994; Chap. 17. 
34. Tomlinson, A. J.; Benson, L. M.; Johnson, K. L.; Naylor, S. J. 
Chromatogr. 1993, 622, 239. 
35. Tomlinson, A. J.; Benson, L. M.; Johnson, K. L.; Naylor, S. 
Electrophoresis 1994, 25, 62. 
36. Tomlinson, A. J.; Benson, L. M.; Gorrod, J. W.; Naylor, S. J. 
Chromatogr. 1994, 657,373. 
37. Eyles, D. W.; McLennan, H. R.; Jones, A.; McGrath, J. J.; 
Stedman, T. J.; Pond, S. M. Clin. Pharmacol. Ther. 1994, 56, 
512. 
38. Rollema, H.; Skolnik, M.; D’Engelbronner, J.; Igarashi, K.; 
Usuki, E.; Castagnoli, N., Jr. 1. Pharm. Expt. Therapeutics 1994, 
268, 380. 
39. Janeway, Jr. Sci. Ann. 1993, 269, 72. 
40. Hunt, D. F.; Henderson, R. A.; Shabanowitz, J.; Sakaguchi, K.; 
Michel, H.; Sevilir, N.; Cox, A. L.; Apella, E.; Engelhard, V. H. 
Science 1992, 255, 1261. 
41. Kyle, R. A.; Lust, J. A. Adu. Clin. Chem. 1990, 28, 145. 
42. Tripathi, R. C.; Millard, C. B.; Tripathi, B. J., Expt. Eye Res. 
1989, 48, 117. 
